To compare the efficacy and safety of EUS guided combined application of thrombin and cyanoacrylate injection with EUS guided cyanoacrylate injection alone for the management of patients with gastroesophageal varices: A randomized control trial - NIL

Start Date20 Jan 2024

Sponsor / Collaborator-

CTRI/2020/07/026466 / RecruitingPhase 3IIT

ENDOSCOPIC GLUE INJECTION VS ENDOSCOPIC HUMAN THROMBIN INJECTION FOR BLEEDING GASTRIC VARICES â?? A RANDOMISED CONTROLLED TRIAL

Start Date15 Jul 2020

Sponsor / Collaborator

SMS Medical College & Hospital

NCT00859547 / CompletedPhase 4

A Phase 4, Open-Label, Single-Group Safety and Immunogenicity Study of RECOTHROM® (rThrombin) in Pediatric Subjects Undergoing Synchronous Burn Wound Excision and Skin Grafting

The objective of this study is to assess the safety and immunogenicity of recombinant thrombin (rThrombin) administered as an aid to hemostasis during burn wound excision and skin grafting in pediatric patients, newborn through 17 years of age.

Start Date01 Mar 2009

Sponsor / Collaborator

ZymoGenetics, Inc.

100 Clinical Results associated with Thrombin alfa(ZymoGenetics)

100 Translational Medicine associated with Thrombin alfa(ZymoGenetics)

100 Patents (Medical) associated with Thrombin alfa(ZymoGenetics)

Literatures (Medical) associated with Thrombin alfa(ZymoGenetics)

14 Sep 2021·Journal of Investigative SurgeryQ4 · MEDICINE

A Comparative Efficacy Evaluation of Recombinant Topical Thrombin (RECOTHROM^®) With A Gelatin Sponge Carrier Versus Topical Oxidized Regenerated Cellulose (TABOTAMP^®/SURGICEL^®) In A Porcine Liver Bleeding Model

Q4 · MEDICINE

Article

Author: Slezak, Paul ; Labahn, Dirk ; Keibl, Claudia ; Genyk, Yuri ; Gulle, Heinz ; Schmidbauer, Anna

PURPOSETopical hemostatic agents can be classified as active or passive. This study compared the hemostatic efficacy of an active agent, recombinant thrombin (RECOTHROM^® [rT]) plus gelatin sponge carrier versus a passive agent, oxidized regenerated cellulose (TABOTAMP^®/SURGICEL^® [ORC]), in a porcine liver abrasion model.MATERIALS AND METHODSEight pigs were used, four of them were heparinized. A total of 80 liver lesions were created, 40 of them in heparinized pigs. Lesions were treated with rT plus gelatin sponge or ORC. Bleeding rate was quantified before treatment by applying pre-weighed gauze. Time to hemostasis was assessed visually for 10 minutes.RESULTSSeven of the 80 lesions were excluded for having initial bleeding rates exceeding the target of 10 g/min. Sixteen and 20 lesions were treated with rT plus gelatin sponge and 19 and 18 lesions were treated with ORC, in non-heparinized and heparinized animals, respectively. Time to hemostasis (median [IQR]) was significantly shorter with rT plus gelatin sponge (30 [30,30] seconds) in heparinized and non-heparinized animals versus ORC in non-heparinized (180 [120,210] seconds) and heparinized animals (215 [135,345] seconds); P < 0.0001 for both comparisons. In heparinized animals, ORC took longer to achieve hemostasis, with treatment failure in 2/18 lesions. Time to hemostasis with ORC was longer for lesions in heparinized animals with initial bleeding rates of >5-10 g/min (285 [225,394] seconds) versus ≤5 g/min (175 [108,290] seconds).CONCLUSIONSIn this model, rT plus gelatin sponge carrier (active) was a more effective hemostat than ORC (passive) in both heparinized and non-heparinized animals.

01 Jul 2019·MenopauseQ3 · MEDICINE

Topical estrogen prescribing patterns for urogenital atrophy among women with breast cancer: results of a national provider survey

Q3 · MEDICINE

Article

Author: Pollack, Craig E ; Richter, Lee A ; Lynce, Filipa C ; Tefera, Eshetu ; Willey, Shawna C ; Han, Jim ; Bradley, Sarah

AbstractObjective:The aim of the study was to evaluate knowledge, attitudes, and practice patterns of physicians prescribing topical estrogen for women with urogenital atrophy and a history of breast cancer.Methods:A cross-sectional survey of breast surgeons, urogynecologists, and gynecologists was distributed via their professional societies: the American Society of Breast Surgeons (ASBrS), the American Urogynecologic Society (AUGS), and the Society of Gynecologic Surgeons (SGS). Providers reported level of comfort prescribing vaginal estrogen for urogenital symptoms for women with different categories of breast cancer and current treatment: estrogen receptor (ER) negative, ER positive no longer on endocrine therapy, and ER positive currently on adjuvant endocrine therapy. General knowledge questions assessed agreement on a 5-point Likert scale to statements about vaginal estrogen safety and pharmacology.Results:A total of 820 physicians completed the survey: 437 responses from the ASBrS (response rate, 26.7%), 196 from AUGS (15%), and 187 from SGS (44.5%). The majority of physicians (84%), regardless of specialty, felt comfortable prescribing vaginal estrogen to women with a history of ER-negative cancer: 65.7% felt comfortable prescribing for women with ER-positive breast cancer no longer on endocrine therapy; 51.3% for women on an aromatase inhibitor; and 31.4% for women on tamoxifen. Urogynecologists were significantly more comfortable than breast surgeons prescribing vaginal estrogen for the lowest risk patients, whereas breast surgeons had the highest level of comfort for women currently on endocrine therapy.Conclusions:This study highlights heterogeneity in practice patterns both within and across specialties. The clinical variation seen in this study suggests providers may benefit from increased knowledge regarding vaginal estrogen.

01 Nov 2018·Obstetrics & GynecologyQ2 · MEDICINE

Topical Estrogen Prescription Fill Rates for Women With a History of Breast Cancer Who Are Taking Hormone Therapy

Q2 · MEDICINE

Article

Author: Amanda L. Blackford ; Craig E. Pollack ; Joseph H. Huntley ; Oluseyi Aliu ; Lee A. Richter

OBJECTIVE:To evaluate how often women with a history of breast cancer who are taking hormone therapy (HT) filled prescriptions for topical estrogens and whether this frequency varied over time and by type of HT used.METHODS:We performed a retrospective cohort study using medical and outpatient drug claims from a large commercial claims database for the years 2010–2015. Women younger than age 65 years taking HT for breast cancer were classified as users of 1) tamoxifen only, 2) aromatase inhibitor(s) only, or 3) any other or multiple HTs. Our outcome variable was filling a prescription for topical estrogen in a given year. We used multivariable logistic regression models estimated with generalized estimating equations to determine whether the fill rate varied over time and by HT category adjusting for age, receipt of surgical or radiation treatment, types of outpatient health care provider visits, and comorbidities.RESULTS:We identified 352,118 records from 176,012 unique patients (mean age 54.3 years, range 18–64 years) who met eligibility criteria. Aromatase inhibitors were used more commonly (56.0% of patient-years) than tamoxifen (38.8%). Overall, 3.0% (range 2.9–3.1%) of women filled any topical estrogen prescription in a given calendar year. More than half of filled topical estrogen prescriptions were for tablets (57.0%) with the remainder for creams (25.8%) and rings (17.3%). In adjusted analyses, the fill rate for women taking tamoxifen was significantly less (2.4%; 95% CI 2.3–2.5%) than for women taking aromatase inhibitors (3.3%; 95% CI 3.2–3.4%). There was a small but statistically significant increase in fill rates across years (odds ratio 1.03, 95% CI 1.02–1.04).CONCLUSION:A small proportion of women with a history of breast cancer who were taking HT filled a topical estrogen prescription, with significant differences by type of HT. More evidence is needed to inform national guidelines regarding safety and appropriate use of topical estrogens in this patient population.

News (Medical) associated with Thrombin alfa(ZymoGenetics)

13 Sep 2021

·www.biospace.com

Bovine Blood Plasma Derivatives Market is Estimated to Rise Profitably during the Foreseeable Future

Development in the healthcare sector has also been of the key focus in North American region. A similar growth and development is seen in the bovine blood plasma derivatives market that made North America a leading region. Presence of key players that are making constant efforts through research and development activities in this region is the major reason for the growth of this region in the global bovine blood plasma derivatives market. Apart from investment made in R&D, leading players are also establishing relationship by initiating mergers and acquisition with other companies mainly to extend their geographical presence. On the other hand, Asia Pacific is also expected to offer lucrative growth opportunities for the stakeholder in the global bovine blood plasma derivatives market. Rising initiative taken by governments in different regions is giving approvals to export products such as serum and cattle protein is considered as key factor behind Asia Pacific bovine blood plasma derivatives market growth. Demand for bovine blood plasma derivatives is high in India, China, and from countries in Southeast Asia that made this region a key market. Request Brochure of Report - Besides, geographical growth of the global bovine blood plasma derivatives market, the revenue generation in this market is also expected to rise significantly in the coming years. Based on the Transparency Market Research on the global bovine blood plasma derivatives market, revenue generation is expected to reach US$2.19 billion by the end of 2025. This figure is substantially high that the revenue earned in 2016 that is US$1.33 billion, thus creating an incremental opportunity of nearly US$ 0.86 billion over the forecast period between 2017 and 2025. Request for Analysis of COVID-19 Impact on Bovine Blood Plasma Derivatives Market - Development of New Drugs through R&D – A Key Strategy Used by Players Players operating in the global bovine blood plasma derivatives market are focusing on various business development strategies to increase their shareholding in the market. In terms of market structure, this market is fragmented in nature due to the presence of large number of players. Prominent players analyzed in this report include Rocky Mountain Biologicals Inc., Thermo Fisher Scientific, Inc., Proliant Inc., Auckland BioSciences Ltd., Sigma-Aldrich Co. (Merck KGaA), Bovogen Biologicals Pty Ltd., and Lake Immunogenics, Inc. Besides, the leading players, presence of large number of small players are also seen in the global market. For example, LAMPIRE Biological Laboratories acquired about 180+ acre corporate dairy farms in Bedford County, Pennsylvania. After this initiative, LAMPIRE Biological Laboratories planned to offer valuable biological raw materials to research and diagnostic companies across the globe. Buy Bovine Blood Plasma Derivatives Market Report at Increasing Application of Thrombin Due To High R&D Likely to Benefit Market’s Growth In terms of derivatives types, the demand for thrombin is comparatively higher than fibrinogen, immunoglobulin, new born calf serum, fetal bovine serum, serum albumin, transferrin, and others including BGG. According to the report, the thrombin segment held larger share in 2017, as compared to other derivatives types. This rise was mainly because of its increasing usage during surgeries and diagnostic purposes. Increasing research and development activities including as medical research, in vitro study, protein structure analysis, biochemical, coagulation research has augmented application of thrombin. Moreover, there are high chances of growth of bovine serum albumin in the coming years and stand at the second position by the end of forecast period. Applications of bovine serum albumin are seen in the drug formulation, food industry, and as a component of media for cell culture. Its use is also seen in the manufacturing several vaccines and in cell culture related work, comprising effective washing of cells and cryopreservation. About Us Transparency Market Research is a next-generation market intelligence provider, offering fact-based solutions to business leaders, consultants, and strategy professionals. Our reports are single-point solutions for businesses to grow, evolve, and mature. Our real-time data collection methods along with ability to track more than one million high growth niche products are aligned with your aims. The detailed and proprietary statistical models used by our analysts offer insights for making right decision in the shortest span of time. For organizations that require specific but comprehensive information we offer customized solutions through ad hoc reports. These requests are delivered with the perfect combination of right sense of fact-oriented problem solving methodologies and leveraging existing data repositories. TMR believes that unison of solutions for clients-specific problems with right methodology of research is the key to help enterprises reach right decision. Contact Mr. Rohit Bhisey Transparency Market Research State Tower, 90 State Street, Suite 700, Albany NY - 12207 United States USA - Canada Toll Free: 866-552-3453 Email: sales@transparencymarketresearch.com Website:

VaccineAcquisition

08 Apr 2008

·www.biospace.com

Haemacure Corporation Announces Details of its Annual General and Special Meeting of Shareholders

MONTREAL, April 7 /PRNewswire-FirstCall/ - Haemacure Corporation , a Montreal-based specialty bio-therapeutics company, will hold its Annual General and Special Meeting of Shareholders on Wednesday, April 9, 2008 at 4 p.m. at The National Club, 303 Bay Street, Toronto, Ontario. Presentation Mr. Joseph Galli, Chairman and Chief Executive Officer of Haemacure, will report on accomplishments of 2007 and provide an outlook for 2008 and beyond, including a report on Haemacure's clinical programs for its two proprietary, human product candidates, a fibrin sealant and an active, topical hemostatic agent (thrombin). Live Webcast For those who are unable to attend in person, Haemacure will simultaneously host a live webcast of the presentation with slides, at About Haemacure Haemacure Corporation is a specialty biotherapeutics company developing high-value human plasma-derived protein products for commercialization. Haemacure's research and development effort is driven by its proprietary plasma protein extraction technology to develop next-generation products, including surgical hemostats. Haemacure's lead product candidate, Hemaseel(R)HMN, is a fibrin sealant to enter pivotal Phase II/Phase III clinical trials during the first quarter of 2009. Haemacure's second product candidate is thrombin, a component of its fibrin sealant. Follow-on development will focus on surgical hemostats, adhesion prevention, regenerative medecine, drug delivery and combinations with biomaterials. Haemacure has identified eleven additional specialty proteins and enzymes in one if its two plasma fractions and seeks to advance these proteins and enzymes through partnerships with pharmaceutical and biotechnology companies. Haemacure operates offices in Sarasota, Florida through a wholly-owned subsidiary. The Corporation is traded under stock symbol HAE on the TSX. Forward-looking Statements Certain of the statements contained in this news release are forward-looking statements. Such statements, based as they are on the current expectations of management, inherently involve numerous risks and uncertainties, known and unknown. Some examples of known risks are: the impact of general economic conditions, general conditions in the biotech industry, changes in the regulatory environment in the jurisdictions in which Haemacure does business, stock market volatility, fluctuations in costs, and changes to the competitive environment due to consolidation or otherwise. Consequently, actual future results may differ materially from the anticipated results expressed in the forward-looking statements. Haemacure disclaims any intention or obligation to update these statements. CONTACT: Haemacure Corporation: Joseph Galli, Chairman and CEO, (514) 990-7074, jgalli@haemacure.ca; Diane Roch, Director, Communications and Investor Relations, (514) 282-3350 ext. 27, Mobile: (514) 952-3350, droch@haemacure.ca;

09 Oct 2006

·www.biospace.com

Johnson & Johnson Wound Management Introduces Applicator Tip That Delivers Hemostat Right Where The Surgeon Needs It

SOMERVILLE, N.J., Oct. 9 /PRNewswire/ -- Johnson & Johnson Wound Management, a division of ETHICON, INC., announced today the launch of SURGIFLO* Hemostatic Matrix with FlexTip, the only pre-filled, flowable hemostat that offers surgeons the option to customize the consistency of the product, now with a flexible tip for precise placement. "The new FlexTip enhances my visibility by managing bleeding fast without interfering with my line of sight," said Robert J. Banco, MD, Chief, Spine Section, New England Baptist Hospital. "Since I work through small incisions during minimally invasive spine surgery, the new tip provides easy access to the hard-to-reach bleeding sites." The new bendable applicator tip has "memory" to ensure it stays at the optimum angle for easier access and exact product placement. The product, SURGIFLO Hemostatic Matrix flows easily into rough or uneven surfaces for complete coverage and rapid hemostasis. When mixed with thrombin, it has been shown to achieve hemostasis in less than two minutes in an in vivo animal spleen model.(1) "SURGIFLO Hemostatic Matrix provides fast hemostasis during sinus with minimal complications," stated Rick Chandra, MD, Clinical Assistant Professor of ENT surgery at the University of Tennessee. "The addition of the FlexTip allows me to navigate through challenging anatomies, permitting accurate placement and minimizing the need to flood cavities with too much product." SURGIFLO Hemostatic Matrix is indicated for surgical procedures (except urologic and ophthalmic) for hemostasis, when control of capillary, venous and arteriolar bleeding by pressure, ligature and other conventional procedures is ineffective or impractical. SURGIFLO Hemostatic Matrix can be used with or without thrombin to achieve hemostasis. SURGIFLO Hemostatic Matrix cannot be used in the closure of skin incisions because it may interfere with the healing of skin edges. It is not indicated for use in intravascular compartments because of the risk of embolization. It is not for use in patients with known allergies to porcine gelatin. SURGIFLO Hemostatic Matrix is not intended as a substitute for meticulous surgical technique and the proper application of ligatures or other conventional procedures for hemostasis. It should not be used in the presence of infection and should be used with caution in contaminated areas of the body. SURGIFLO Hemostatic Matrix should not be used in instances of pumping arterial hemorrhage or where blood or other fluids have pooled or in an instance where the point of hemorrhage is submerged. It should be removed, if possible, once hemostasis is achieved. When using around or in proximity to foramina in bone, areas of bony confine, the spinal cord, and/or the optic nerve and chiasm, SURGIFLO Hemostatic Matrix should not be used for controlling post-partum intrauterine bleeding or menorrhagia. For full prescribing information visit . About Johnson & Johnson Wound Management Johnson & Johnson Wound Management, a division of ETHICON, INC., a Johnson & Johnson company, continues the company's 100-year commitment to skin and wound care today with inventive products for chronic and acute wound management, and hemostasis. For more information about SURGIFLO Hemostatic Matrix with FlexTip, Johnson & Johnson Wound Management or other ETHICON divisions, call 877-384-4266 in the United States or visit or . * Trademark (1) Data on File, ETHICON, INC. ETHICON, INC. CONTACT: Brieann Szatkowski, ETHICON, INC., +1-908-218-2783 Web site:

100 Deals associated with Thrombin alfa(ZymoGenetics)

External Link

KEGG	Wiki	ATC	Drug Bank
-	-	-	DB11572

R&D Status

10 top approved records.

to view more data

Indication	Country/Location	Organization	Date
Hemorrhage	US	ZymoGenetics, Inc.	17 Jan 2008
Hemorrhage	US	Baxter Healthcare Corp.	17 Jan 2008

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


DDW2021	Not Applicable	Bleeding gastric varices	-	Thrombin	wsqtpflrkw(skfwzrrrtk) = 1 case sgkrpithgo (bxnephwrmm ) View more	-	23 May 2021
DDW2021	Not Applicable	Bleeding gastric varices	-	Thrombin	prjntfrhiu(nuwxtszepg) = 1 case haxgyseivx (rcsaplasnl ) View more	-	23 May 2021
DDW2021	Not Applicable	Bleeding gastric varices	-	Thrombin	mtlfbvezki(sbuqpggxxx) = 1 case sxsbthnaha (jfyynbzntx ) View more	-	23 May 2021
DDW2021	Not Applicable	Bleeding gastric varices	-	Thrombin	tgouhjcpmv(sosudyahuq) = 1 case lajandqixc (skfxmuoslj ) View more	-	23 May 2021
DDW2021	Not Applicable	Bleeding gastric varices	-	Thrombin	pivbusoqci(npmqfsxspu) = 1 case orsbpeateg (pbnoyjgbzr ) View more	-	23 May 2021
UEGW	Not Applicable	Aneurysm, False	-	EUS-guided thrombin injection	(ilvbydvmkw) = mjssowvxon lkknwijgzj (fbvylsflrw, 4.2 - 9.3) View more	-	01 Oct 2020
UEGW	Not Applicable	-	-	EUS-guided thrombin injection	(sbuyadjvck) = azlyiklooq szgbufwcrp (qcafvogjyz, 4.1 - 12.2) View more	-	01 Oct 2019
NCT00813904 (CTgov)	Phase 4	Blood Loss, Surgical	31	rThrombin, 1000 IU/mL	ngvbksbzvj(vblohqzwvd) = fvrfhgypod jnchmmiqcq (lacefmnxfn, qdwttubzrb - jnzfryujbx) View more	-	08 Dec 2011
ASN2011	Not Applicable	Nephritis, Interstitial	-	Thrombin	mkpfhwbsnh(ucwzkbhebi) = leijihhmgi crtipantdk (xcquvngkiz )	-	08 Nov 2011
Pubmed \| J Am Coll Surg	Phase 3	Blood Loss, Surgical	209	Topical recombinant thrombin	pwixgpofct(oqoxndorjq) = trdxeiqpdy jqxgyxtqwb (uyobhrgwgt )	-	01 Jul 2009

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

Chat with Hiro

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis